Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Women's Health
Published in: BMC Women's Health 1/2012

Open Access 01-12-2012 | Research article

A population-based study of Kurdish breast cancer in northern Iraq: Hormone receptor and HER2 status. A comparison with Arabic women and United States SEER data

Authors: Runnak A Majid, Hazha A Mohammed, Hemin A Hassan, Wasan A Abdulmahdi, Rekawt M Rashid, Michael D Hughson

Published in: BMC Women's Health | Issue 1/2012

Login to get access

Abstract

Background

Hormone receptor (HR) and HER2 expression predict the therapeutic response and prognosis of breast cancer. In the Middle-East, breast cancer is diagnosed at a young age, and Arabic women are reported to have a low frequency of HR positive tumors. This study investigates HR and HER2 expression among Kurdish and Arabic women.

Methods

During 2008–2010, the Sulaimaniyah Directorate of Health records identified 514 Sulaimaniyah Kurdish women, 227 Kurdish women of other Governates, and 83 Arabic women with a first diagnosis of breast cancer. The breast cancers of 432 women had immunohistochemistry (IHC) performed for estrogen and progesterone receptors (ER and PR) and HER2. Age specific and age standardized incidence rates were calculated for Sulaimaniyah Kurds. Results were compared with Egypt and with United States (US) SEER data.

Results

The median patient age was 46 years and 60.4% were < 50 years old. Tumors of 65.2% of women were ER+/HER2- with the rate increasing to 78.3% in patients ≥ 60 years old in proportions similar to US whites. The total annual age standardized incidence for breast cancer among Sulaimaniyah Kurds was 40.5/100,000 women, a rate similar to Egypt but much lower than the US. By HR/HER2 subtype, the highest age specific incidence rates were 16.4 and 45.4/100,000 for ER+/PR+/HER2- tumors in women < 50 or ≥ 50 years old, respectively (US whites: 37.7 and 226.1/100,000). Tumors of 20.4% of Sulaimaniyah women were HER2+ with annual incidence rates for ER-/PR-/HER2+ tumors of women <50 or ≥ 50 years old being 4.0 and 6.3/100,000 (US whites: 3.2 and 14.4/100,000). No significant differences in ER or HER2 status were found between Kurdish and Arabic patients.

Conclusions

Compared to the US, low age standardized and age specific breast cancer incidence rates were found in Kurdish women; nevertheless, the proportional expression of HR and HER2 for both Kurds and Arabs was comparable to that of US white women. The great majority of the breast cancer was ER+/HER2- and should respond to anti-estrogen therapy.
Literature
1.
Dunnwald LK, Rossing MA, Li CI: Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Research. 2007, 9: R6-10.1186/bcr1639.CrossRefPubMedPubMedCentral
2.
Li CI, Malone KE, Daling JR: Differences in breast cancer stage, treatment, and survival by race and ethnicity. Arch Intern Med. 2003, 163: 49-56. 10.1001/archinte.163.1.49.CrossRefPubMed
3.
Chlebowski RT, Chen Z, Anderson GL, Rohan T, Aragaki A, Lane D, Dolan NC, Paskett ED, McTiernan A, Hubbell FA, Adams-Campbell LL, Prentice R: Ethnicity and breast cancer: factors influencing differences in incidence and outcome. J Natl Cancer Inst. 2005, 97: 439-448. 10.1093/jnci/dji064.CrossRefPubMed
4.
Gapstur SM, Dupuis J, Gann P, Collila S, Winchester DP: Hormone receptor status of breast tumors in black, Hispanic, and non-Hispanic white women. An analysis of 13,239 cases. Cancer. 1996, 77: 1465-1471. 10.1002/(SICI)1097-0142(19960415)77:8<1465::AID-CNCR7>3.0.CO;2-B.CrossRefPubMed
5.
Li CI, Malone KE, Daling JR: Differences in breast cancer hormone receptor status and histology by race and ethnicity among women 50 years of age and older. Cancer Epidemiol Biomarkers Prev. 2002, 11: 601-607.PubMed
6.
Anderson WF, Chatterjee N, Ershler WB, Brawley OW: Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. Breast Cancer Res Treat. 2002, 76: 27-36. 10.1023/A:1020299707510.CrossRefPubMed
7.
Lund MJ, Butler EN, Hair BY, Ward KC, Andrews JH, Oprea-Ilies G, Bayakly AR, O'Regan RM, Vertino PM, Eley JW: Age/race differences in HER2 testing and in incidence rates for breast cancer triple subtypes: a population-based study and first report. Cancer. 2010, 116: 2549-2559.PubMed
8.
Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC: Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006, 295: 2492-2502. 10.1001/jama.295.21.2492.CrossRefPubMed
9.
SEER Cancer Statistics Review, 1975–2005. Edited by: Ries LAG, Melbert D, Krapcho M, Stinchcomb DG, Howlader N, Horner MJ, Mariotto A, Miller BA, Feuer EJ, Altekruse SF, Lewis DR, Clegg L, Eisner MP, Reichman M, Edwards BK. 2008, National Cancer Institute, Bethesda, MD, http://​seer.​cancer.​gov/​csr/​1975_​2005/​, based on November 2007 SEER data submission, posted to the SEER web site
10.
Furberg H, Millikan R, Dressler L, Newman B, Geradts J: Tumor characteristics in African American and white women. Breast Cancer Res Treat. 2001, 68: 33-43. 10.1023/A:1017994726207.CrossRefPubMed
11.
Porter PL, Lund MJ, Lin MG, Yuan X, Liff JM, Flagg EW, Coates RJ, Eley JW: Racial differences in the expression of cell cycle-regulatory proteins in breast carcinoma. Cancer. 2004, 100: 2533-2542. 10.1002/cncr.20279.CrossRefPubMed
12.
Gown AM: Current issues in ER and HER2 testing by IHC in breast cancer. Mod Pathol. 2008, 21: S8-S15.CrossRefPubMed
13.
14.
Pritchard KI, Shepherd LE, O'Malley FP, Andrulis IL, Tu D, Bramwell VH, Levine MN, National Cancer Institute of Canada Clinical Trials Group: HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med. 2006, 354: 2103-2111. 10.1056/NEJMoa054504.CrossRefPubMed
15.
Gennari A, Sormani MP, Pronzato P, Puntoni M, Colozza M, Pfeffer U, Bruzzi P: HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. J Natl Cancer Inst. 2008, 100: 14-20. 10.1093/jnci/djm252.CrossRefPubMed
16.
Konecny G, Pauletti G, Pegram M, Untch M, Dandekar S, Aguilar Z, Wilson C, Rong HM, Bauerfeind I, Felber M, Wang HJ, Beryt M, Seshadri R, Hepp H, Slamon DJ: Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst. 2003, 95: 142-153. 10.1093/jnci/95.2.142.CrossRefPubMed
17.
Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005, 353: 1673-1684. 10.1056/NEJMoa052122.CrossRefPubMed
18.
Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R, Utriainen T, Kokko R, Hemminki A, Tarkkanen M, Turpeenniemi-Hujanen T, Jyrkkiö S, Flander M, Helle L, Ingalsuo S, Johansson K, Jääskeläinen AS, Pajunen M, Rauhala M, Kaleva-Kerola J, Salminen T, Leinonen M, Elomaa I, Isola J, FinHer Study Investigators: Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. 2006, 354: 809-820. 10.1056/NEJMoa053028.CrossRefPubMed
19.
Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Láng I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Rüschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD, Herceptin Adjuvant (HERA) Trial Study Team: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005, 353: 1659-1672. 10.1056/NEJMoa052306.CrossRefPubMed
20.
Majid RA, Mohammed HA, Saeed HM, Safar BM, Rashid RM, Hughson MD: Breast cancer in kurdish women of northern Iraq: incidence, clinical stage, and case control analysis of parity and family risk. BMC Womens Health. 2009, 9: 33-10.1186/1472-6874-9-33.CrossRefPubMedPubMedCentral
21.
Rennert G: Breast cancer. Cancer Incidence in the Four Member Countries (Cyprus, Egypt, Israel, and Jordan) of the Middle-East Cancer Consortium (MECC) compared with US SEER, Chapter 8. Edited by: Friedman LS, Edwards BK, Reiss LAG, Young JL. 2006, National Cancer Institute. NIH Pub No. 06–5873, Bethesda, MD, 73-81.
22.
Dey S, Soliman AS, Hablas A, Seifeldin IA, Ismail K, Ramadan M, El-Hamzawy H, Wilson ML, Banerjee M, Boffetta P, Harford J, Merajver SD, Breast Cancer Res Treat: Urban–rural differences in breast cancer incidence by hormone receptor status across 6 years in Egypt. Breast Cancer Res Treat. 2010, 120: 149-160. 10.1007/s10549-009-0427-9.CrossRefPubMed
23.
Sughayer MA, Al-Khawaja MM, Massarweh S, Al-Masri M: Prevalence of hormone receptors and HER2/neu in breast cancer cases in Jordan. Pathol Oncol Res. 2006, 12: 83-86. 10.1007/BF02893449.CrossRefPubMed
24.
Al Tamimi DM, Shawarby MA, Ahmed A, Hassan AK, AlOdaini AA: Protein expression profile and prevalence pattern of the molecular classes of breast cancer-a Saudi population based study. BMC Cancer. 2010, 10: 223-10.1186/1471-2407-10-223.CrossRefPubMedPubMedCentral
25.
Abadjian G, Antoun R: Breast carcinoma: evaluation of hormone receptors and pS2, erb-B2, P-glycoprotein and Ki-67 markers. J Med Liban. 1996, 44: 10-15.PubMed
26.
Ben Abdelkrim S, Trabelsi A, Missaoui N, Beizig N, Bdioui A, Anjorin A, Jomaa W, Mokni M: Distribution of molecular breast cancer subtypes among Tunisian women and correlation with histopathological parameters: a study of 194 patients. Pathol Res Pract. 2010, 206: 772-775. 10.1016/j.prp.2010.07.012.CrossRefPubMed
27.
al-Alwan NA, al-Kubaisy W, al-Rawaq K: Assessment of response to tamoxifen among Iraqi patients with advanced breast cancer. East Mediterr Health J. 2000, 6: 475-482.PubMed
28.
Salhia B, Tapia C, Ishak EA, Gaber S, Berghuis B, Hussain KH, DuQuette RA, Resau J, Carpten J: Molecular subtype analysis determines the association of advanced breast cancer in Egypt with favorable biology. BMC Women’s Health. 2011, 11: 44-10.1186/1472-6874-11-44.CrossRefPubMedPubMedCentral
29.
Benz CC: Impact of ageing and the biology of breast cancer. Crit Rev Oncol Hematol. 2008, 66: 65-74. 10.1016/j.critrevonc.2007.09.001.CrossRefPubMed
30.
Huang HJ, Neven P, Drijkoningen M, Paridaens R, Wildiers H, Van Limbergen E, Berteloot P, Amant F, Vergote I, Christiaens MR: Hormone receptors do not predict the HER2/neu status in all age groups of women with an operable breast cancer. Ann Oncol. 2005, 16: 1755-1761. 10.1093/annonc/mdi364.CrossRefPubMed
31.
Koninki K, Tanner M, Auvinen A, Isola J: HER2 positive in breast cancer: decreasing proportion but stable incidence in Finnish population from 1982 to 2005. Breast Cancer Research. 2009, 11: R37-10.1186/bcr2322.CrossRefPubMedPubMedCentral
32.
Anderson BO: Breast cancer hormone receptor status in Egypt: Are we asking the questions that matter the most?. Breast Cancer Res Treat. 2010, 120: 161-163. 10.1007/s10549-009-0474-2.CrossRefPubMed
33.
Masood S, Vass L, Ibarra JA, Ljung BM, Stalsberg H, Eniu A, Carlson RW, Anderson BO, on behalf of the Breast Health Global Health Initiative Pathology Focus Group: Breast pathology guideline implementation in low- and middle-income countries. Cancer. 2008, 113 (8 Suppl): 2297-2304.CrossRefPubMed
Metadata
Title
A population-based study of Kurdish breast cancer in northern Iraq: Hormone receptor and HER2 status. A comparison with Arabic women and United States SEER data
Authors
Runnak A Majid
Hazha A Mohammed
Hemin A Hassan
Wasan A Abdulmahdi
Rekawt M Rashid
Michael D Hughson
Publication date
01-12-2012
Publisher
BioMed Central
Published in
BMC Women's Health / Issue 1/2012
Electronic ISSN: 1472-6874
DOI
https://doi.org/10.1186/1472-6874-12-16

Other articles of this Issue 1/2012

BMC Women's Health 1/2012 Go to the issue

Research article

Sexual function and chemotherapy in postmenopausal women with breast cancer

Research article

Treatment of endometriosis in different ethnic populations: a meta-analysis of two clinical trials

Research article

Disclosure experience in a convenience sample of quebec-born women living with HIV: a phenomenological study

Research article

Fibroid explants reveal a higher sensitivity against MDM2-inhibitor nutlin-3 than matching myometrium

Research article

An assessment of the likely acceptability of vaginal microbicides for HIV prevention among women in rural Ghana

Research article

Rates of IUCD discontinuation and its associated factors among the clients of a social franchising network in Pakistan